Lupin’s Symbiomix acquisition looks like a step in the right direction2 min read 15 Oct 2017, 11:53 PM IST
Lupin's acquisition of Symbiomix Therapeutics gives it access to a women's healthcare drug brand, Solosec, which has received US drugs regulator USFDA's approval
Lupin Ltd’s acquisition of Symbiomix Therapeutics LLC has provided a glimmer of hope for investors, who have been worried about sliding sales and shrinking profitability. The company’s shares gained 1.8% last week after it announced the acquisition, although, of course, that’s not much when compared with the 28% decline in the past one year.
Select your Category